Half of patients with chronic conditions do not take their medications as prescribed. The CDC puts the annual cost in the United States at $100 to $300 billion and links non-adherence to roughly 125,000 preventable deaths. The World Health Organization has reported the same 50% figure globally for over twenty years. Adherence has not meaningfully improved across that period.
Pharma’s response has been more digital health apps. More reminders. More streaks. More badges for logging a dose. The flat adherence curve over two decades suggests this is the wrong intervention.
Medication adherence design treats non-adherence as a memory failure. It almost never is. A patient who swipes away a reminder is not forgetting. They are choosing not to act. That is a motivation problem, and reminders cannot solve a motivation problem.
This piece walks through what The Octalysis Group sees consistently in client engagements across pharma and digital health, why the most common adherence designs fail, and what the Pfizer Sidekick app got right when the same problem was tackled through behavioral design.
What Reminders and Points Do
A patient on a daily statin gets nothing felt from taking the pill. They do not feel better today. They will not feel worse tomorrow if they skip. The clinical benefit is invisible and located years away. Asking that patient to perform a daily effortful action with no felt reward is asking for a sustained motivational lift that the design itself is not providing.
Reminders activate one drive: Loss & Avoidance. Take the pill or face the consequences. This works briefly, then collapses. The fastest way to stop the anxiety produced by a fear-based app is to uninstall it. Across 175 client engagements, this is the single most consistent failure pattern in adherence design. Apps that pressure patients get deleted by the patients who most need them.
Adding points on top does not solve this. Development & Accomplishment can sustain engagement when the progression feels meaningful to the patient. A trophy for logging a pill is not meaningful to an adult managing diabetes. Once the novelty fades, so does the behavior. The system has stacked two weak drives on top of each other and called it gamification.
The Drives Adherence Design Keeps Ignoring
The Octalysis Framework identifies eight Core Drives of human motivation. Most adherence apps overuse two of them and ignore four that matter more for long-term behavior change.
Epic Meaning & Calling changes what taking a pill represents. Patients who connect treatment to a concrete personal purpose adhere at higher rates than patients managing an abstract future risk. The medication stops being a reminder of illness. It becomes part of something the patient already wants for themselves.
Empowerment of Creativity & Feedback restores agency. Chronic illness strips autonomy away from patients across every part of their lives. Design that lets the patient configure their own tracking, run their own experiments with routine and timing, and see real feedback about how their body responds works better than rigid protocols. The patient is solving a problem rather than following instructions.
Social Influence & Relatedness addresses isolation. Chronic disease is privately experienced, and most adherence apps keep it that way through one-to-one brand-to-patient interaction. Patients connected to others with the same diagnosis, through structured peer support, shared challenges, or community accountability, sustain adherence at higher rates than patients managing alone.
Ownership & Possession turns the platform itself into a sunk-cost asset. A patient who has spent weeks customizing an interface, logging biometric history, and building a personal record of how their condition behaves does not switch apps easily. The platform has become part of how they manage their life, not a tool they tolerate.
Most adherence design ignores all four of these. The defaults are points and reminders, which is the motivational equivalent of using one hand to lift a piano.
What Pfizer Sidekick Got Right
When Pfizer came to The Octalysis Group, the brief was familiar. Functional reminder tools were not improving adherence on complex therapeutic regimens. Patients were dropping out. Engagement was shallow. The brand wanted something different.
The work produced Sidekick, a digital health companion designed around behavioral science rather than around notification logic. Sidekick tracks sleep, nutrition, emotional state, and adherence in a single feedback loop, so patients can see how their daily choices connect to how they feel rather than just whether a pill was logged. Patients build a personal track record they own over time. The design uses Ownership & Possession to make the platform a habit asset rather than a daily nag, and integrates Epic Meaning & Calling by framing health management around what matters to each patient rather than around clinical compliance.
The case study is documented on the Octalysis Group site and through our broader client work. The point for any pharma team looking at adherence is not that one app worked. The point is the order of operations. Sidekick did not start with technology decisions. It started with a behavioral audit of why patients were not engaging, which drives were missing, and what would have to change for adherence to feel like something the patient was choosing rather than something they were being managed into.
The Implications
Three observations from work across pharma and digital health are worth taking seriously if your adherence product is showing flat engagement.
The first is that fear-based design produces avoidance of the design. Patients with chronic conditions are already carrying anxiety about their health. Adding an app that amplifies that anxiety does not increase adherence. It increases uninstalls. The Octalysis Framework refers to fear-driven motivation as Black Hat design, useful in short bursts but corrosive in long-term contexts like chronic disease management.
The second is that points alone cannot carry a system. Development & Accomplishment is a real drive, but it requires the progression to feel meaningful. Logging a pill for a digital sticker does not. Long-term progress visualization, milestones that map to the patient’s actual condition, and feedback that makes invisible biology visible all work better than badges.
The third is that the patient is not a compliance subject. They are a person managing a difficult ongoing situation, often alone. Design that respects their intelligence, gives them agency, connects them to others in the same situation, and frames the work as something they own produces durable engagement. Design that treats them as a behavior to be modified through notifications produces the curve the entire industry has been stuck on for twenty years.
The path forward in medication adherence design is not better notification copy. It is a different starting point. Audit which drives are present, identify which are missing, and rebuild around the motivation rather than around the alarm clock.
Contact us for a behavioral audit of your patient engagement product. Browse our case studies to see how this works across pharma and other industries.